This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT07281495 |
|---|---|
| Status | Active not recruiting |
| Phase | Phase 2 |
| Sponsor | Biohaven Therapeutics Ltd. |
| Enrollment | 150 participants |
| Design | Interventional, Randomized, Parallel, Masking: Quadruple |
| Conditions | Obesity; Overweight |
| Interventions | Taldefgrobep Alfa; Placebo; Taldefgrobep Alfa; Placebo |
| Start | Nov 24, 2025 |
| Primary completion | Sep 2026 |
| Study completion | Sep 2026 |
| Results posted | Not yet |
| Registry last updated | Mar 20, 2026 |
Compounds on this site that cite this trial
What the registry says the trial is about
This is a multicenter, randomized, double-blind, placebo-controlled, multiple dose study to evaluate the efficacy, safety, and tolerability of taldefgrobep alfa in adults with overweight and obesity, with an open-label extension.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Percent change in total body weight from Baseline to Week 24 | Baseline to Week 24 |
3 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Oct 30, 2026. See the trial changes feed for what has changed recently.
More trials of Taldefgrobep alfa
Research area: Related non-peptide compounds. Every registered trial we follow is in the clinical trial tracker, and the labels used on this page are explained in our evidence standards.
